Monopar Therapeutics (MNPR) Shares Outstanding (2016 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Shares Outstanding (Entity) data on file, last reported at $6.7 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Entity) rose 76.56% year-over-year to $6.7 million; the trailing twelve-month figure through Dec 2025 stood at $6.7 million (up 76.56% YoY), and the FY2025 full-year result was $6.7 million, up 76.56% from the prior year.
• Shares Outstanding (Entity) held at $6.7 million in Q4 2025, from $6.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $6.7 million in Q4 2025 to a low of $2.5 million in Q1 2021.
• A 5-year average of $3.6 million and a median of $2.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) advanced 0.4% in 2022 and surged 89.02% in 2025, its largest moves.
• Tracing MNPR's Shares Outstanding (Entity) over 5 years: stood at $2.5 million in 2021, then gained by 2.77% to $2.6 million in 2022, then advanced by 15.12% to $3.0 million in 2023, then gained by 27.15% to $3.8 million in 2024, then surged by 76.56% to $6.7 million in 2025.
• Business Quant data shows MNPR's Shares Outstanding (Entity) at $6.7 million in Q4 2025, $6.7 million in Q3 2025, and $6.1 million in Q2 2025.